Ipamorelin 5MG

Product Overview

Ipamorelin 5MG is a synthetic growth-hormone secretagogue research material, supplied as white to off-white lyophilised powder in a 5mg catalogue presentation (SKU IP5). This page describes the stated research identity and batch-oriented catalogue specification; it does not provide an administration protocol.

Ipamorelin is studied as a ghrelin-receptor agonist with growth-hormone secretagogue activity. Research has examined receptor selectivity, pituitary signalling and GH/IGF-axis responses in preclinical and limited human contexts.

Identity and Specifications

• Product: Ipamorelin 5MG
• SKU: IP5
• Format: White to off-white lyophilised powder
• Synonyms: Ipamorelin, NNC-26-0161, Aib-His-D-2-Nal-D-Phe-Lys-NH2
• Catalogue purity specification: ≥99%
• CAS number: 170851-70-4
• Molecular formula: C38H49N9O5
• Molecular weight: 711.9 g/mol
• Amount: 5mg

Catalogue Distinction

This is the 5mg listing for this identity. The related Ipamorelin 10mg listing has a different labelled amount or volume and a separate SKU. The amount difference is not a dose recommendation. Unless a batch certificate states otherwise, the scientific identity and research limitations are shared while the quantity supplied differs.

Research Context

The following themes summarise published research on the named molecule or components. They are research contexts, not claims about the supplied ExtolX batch.

Areas of Research

• ghrelin-receptor pharmacology
• growth-hormone secretagogue selectivity
• pituitary and GH/IGF-axis signalling
• comparative secretagogue assay design

Evidence Quality and Limitations

The evidence base is largely pharmacological and preclinical, with limited clinical literature. It does not establish clinical efficacy, safe administration or equivalence of this research vial to any studied formulation.

Storage and Handling

Before reconstitution: Keep the lyophilised vial sealed, dry and protected from light at −20°C, subject to the batch-specific supplier documentation. Published ipamorelin reference data use the acetate form, but the free-base or acetate form of this ExtolX batch has not been confirmed.

After reconstitution: The published acetate reference advises against storing aqueous solution for more than one day. Longer periods reported for free-base material must not be transferred to an unverified formulation. Prepare solution fresh where the validated method permits and record the solvent, concentration, preparation time, temperature and container used.

Compatibility Limitations

Do not infer solubility or stability from another peptide, blend, amount or pharmaceutical formulation. Use small-scale method development and appropriate analytical controls before committing valuable material.

Laboratory Safety

Handle only in an appropriately equipped laboratory by trained personnel. Use a task-specific risk assessment, suitable personal protective equipment and applicable safety documentation. Avoid ingestion, inhalation, skin contact and environmental release, and dispose of waste in accordance with local requirements.

Sources

• Cayman Chemical: Ipamorelin acetate storage and solution guidance
• Selective secretagogue study (PMID 9849822)
• GH/IGF-axis animal study (PMID 14630569)
• Ipamorelin 10MG

Scientific sources last reviewed: 23 August 2026.

Research Use Agreement & Disclaimer

For laboratory research use only. Not for human or veterinary use. Purchasers are responsible for lawful handling, storage and disposal in accordance with applicable regulations and good laboratory practice. Product information is educational and is not medical advice or evidence of efficacy.